Axelyf, Inc.

BiotechnologyBiotechnologyRNA TherapeuticsLNP Delivery

📍 Chestnut Hill, MA, USA• Founded 2022

StreetZero Signal 74

Be the first to signal interest

About Axelyf, Inc.

Axelyf, Inc. is a biotechnology company developing next-generation lipid nanoparticle (LNP) delivery systems for RNA therapeutics targeting oncology and autoimmune diseases. Headquartered in Massachusetts with a subsidiary in Iceland, the company combines lipid chemistry, RNA biology, and drug delivery expertise with an AI-driven design platform called ANNA. Its proprietary AXL technology has shown superior in vivo gene editing potency compared to the LP-01 benchmark. The company acquired assets from 76Bio, Inc.

LATEST FUNDINGSeed

$2.6M

Announced 2026-10-13

TOTAL RAISED$2.6M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Axelyf, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED2022

HQChestnut Hill, MA, USA

Industry

Biotechnology

Investors

Brunnur Ventures Omega ehf Silfurberg ehf

Key highlights

Closed $2.6M seed round led by Brunnur Ventures in 2025.
AXL lipids demonstrated higher mouse gene editing efficiency at lower doses than LP-01 with no liver toxicity.
Funding supports ANNA machine learning platform and preclinical NHP studies.
Company acquired assets from 76Bio focused on mRNA and LNP technologies.
CEO and co-founder is Örn Almarsson.